Page last updated: 2024-12-07
desmethylmianserin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Desmethylmianserin is a metabolite of the antidepressant mianserin. It exhibits anti-depressant activity and is believed to be a partial agonist of the 5-HT2A receptor. Research on desmethylmianserin focuses on its potential therapeutic applications, including its antidepressant effects and its role in the treatment of other conditions, such as anxiety and insomnia. Studies have also investigated its pharmacokinetic properties and its interactions with other drugs. The compound's importance lies in its potential to contribute to the development of novel therapeutic agents for various psychiatric disorders.'
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 115194 |
| CHEBI ID | 188043 |
| SCHEMBL ID | 2739027 |
| MeSH ID | M0158507 |
Synonyms (28)
| Synonym |
|---|
| desmethylmianserin |
| (+/-)-demethylmianserin |
| normianserine |
| demethylmianserin |
| 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine |
| nor mianserin |
| 2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene |
| 71936-92-0 |
| CHEBI:188043 |
| AKOS005216265 |
| pi2h4adr4c , |
| dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro- |
| unii-pi2h4adr4c |
| 1,2,3,4,10,14b-hexahydrodibenzo(c,f)pyrazino(1,2-a)azepine |
| org oh 46 |
| FT-0673116 |
| 1,2,3,4,10,14b-hexahydrodibenzo[c,f]-pyrazino[1,2-a]azepine |
| SCHEMBL2739027 |
| 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine # |
| n-desmethylmianserin |
| n-desmethyl mianserin |
| n-desmethyl ms |
| normianserin |
| DTXSID20891477 |
| dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro- |
| mfcd00871853 |
| Q27286570 |
| 2,5-diazatetracyclo[13.4.0.0?,?.0?,??]nonadeca-1(19),8,10,12,15,17-hexaene |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " In 44 depressed patients, subjective side effects during 3 weeks of treatment with 30 mg of mianserin were evaluated by the UKU Side Effect Rating Scale, and their relationships to plasma concentrations of mianserin and desmethylmianserin were analyzed." | ( Subjective side effects of mianserin in relation to plasma concentrations of mianserin and desmethylmianserin. Fukushima, Y; Higuchi, H; Hishikawa, Y; Kaneko, S; Otani, K; Sasa, H, 1992) | 0.69 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "The relationships between the plasma concentrations of mianserin and desmethylmianserin at 18 h after initial dosing and those at steady state were studied in 19 depressed patients receiving 30 mg of mianserin at bedtime." | ( Prediction of plasma concentrations of mianserin and desmethylmianserin at steady state from those after an initial dose of mianserin. Fukushima, Y; Kaneko, S; Mihara, K; Okada, M; Otani, K; Tanaka, O, 1993) | 0.77 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| dibenzooxazepine | An organic heterotricyclic compound consisting of two benzene rings fused to a seven-membered ring containing one oxygen and one nitrogen atom. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (13)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 10 (76.92) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.55
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.55) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (7.14%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||